The development of an effective synthetic route of rilpivirine

BACKGROUND: Rilpivirine (RPV) was approved by the U.S. FDA (Food and Drug Administration) in 2011 to treat individuals infected with human immunodeficiency virus 1 (HIV-1). Significantly, rilpivirine is three fold more potent than etravirine. Once-daily, it is used with a low oral dose (25 mg/tablet...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Chem
Main Authors: Zhang, Tao, Yang, Jiapei, Zhou, Zhongxia, Fu, Zhipeng, Cherukupalli, Srinivasulu, Kang, Dongwei, Zhan, Peng, Liu, Xinyong
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8017658/
https://ncbi.nlm.nih.gov/pubmed/33810807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13065-021-00749-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados